Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome — Stella

Home/Overactive Bladder Syndrome/Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome

View on ClinicalTrials.gov

Recruiting

Back to Overactive Bladder Syndrome trials

Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

United States

Walter Reed National Military Medical Center, Bethesda, Maryland

Key details

Phase

Post-approval study

Sponsor

Walter Reed National Military Medical Center

Enrollment target

~152 participants

Started

October 2022

Primary completion

December 2026

Age range

18 Years and older

Sex

Female only

Last updated August 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.